Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

Enzon Pharmaceuticals

Status and phase: Terminated; Phase 1

Conditions: Neoplasm; Lymphomas; Neoplasm Metastasis

Treatments: Drug: PEG-paclitaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT00023166

PTX-5001

Details and patient eligibility

About

Studies of PEG-paclitaxel have been terminated

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

None - Study has been terminated.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)